NRx Pharmaceuticals, Inc. NRXP
At closeNov 6, 2026, 7:55 PM EST
After hours · Nov 6, 7:55 PM ET
- YTD
- -12.18%
- 1 year
- -10.86%
- Market cap
- 103.04M
- EPS (ttm)
- -0.58
- Shares out
- 12.09M
- Forward P/E
- -1.12
- YTD return
- -12.18%
- 1-year return
- -10.86%
- Volume
- 604.42K
- Avg volume
- 1.14M
- Open
- 2.30
- Previous close
- 2.27
- Day's range
- 2.26 – 2.40
- 52-week range
- 1.68 – 4.62
- Beta
- 1.27
- Price target
- 31.67 (+1230.5%)
- Earnings date
- Aug 14, 2024
ALL -94.33 (-97.65%)
Key statistics
- Enterprise value
- 18.64M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.35M
- Total cash
- 1.90M
- Total debt
- 7.65M
- Return on equity
- 0.00%
- Short % of float
- 7.69%
- 50-day average
- 1.28
- 200-day average
- 2.53
Analyst view
- Target (low)
- 19.00
- Target (mean)
- 31.67
- Target (high)
- 45.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.295.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.81 | -0.15 | +0.66 | +81.48% |
| Aug 14, 2024 | Jun 1, 2024 | -0.81 | -0.75 | +0.06 | +7.41% |
| Aug 14, 2024 | Jun 1, 2024 | -0.81 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.74 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -0.70 | -0.50 | +0.20 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | D. Boral Capital | main | Buy | Buy |
| Oct 30, 2024 | EF Hutton | main | Buy | Buy |
| Oct 21, 2024 | EF Hutton | init | — | Buy |
| Sep 12, 2024 | Ascendiant Capital | main | Buy | Buy |
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nrxpharma.com
News
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday 
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
NRx Pharmaceuticals Receives FDA Approval Of Its Abbreviated New Drug Application For Preservative-Free Ketamine 
Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket 
NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge? 
NRx Pharmaceuticals Completes Three Process Validation Lots Of Preservative Free Ketamine Produced Under Commercial Conditions In Anticipation Of Nov. 10 Generic Drug User Fee Amendments Goal Date 
NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10 
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50 
NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency
Your note
Sign in to keep a note on NRXP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOROVITZ AARON | Director | Purchase | Aug 29, 2023 | 0 |
| HURVITZ CHAIM | Director | Purchase | Aug 29, 2023 | 2,214,790 |
| JAVITT JONATHAN C | Chairman of the Board | Purchase | Dec 16, 2024 | 1,516,830 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.99% | 240,316 | 341.25K | Sep 29, 2024 |
| Anson Funds Management LP | 1.18% | 142,525 | 202.38K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 1.08% | 130,085 | 184.72K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.64% | 77,341 | 109.82K | Sep 29, 2024 |
| Sabby Management, LLC | 0.29% | 35,049 | 49.77K | Sep 29, 2024 |
| Blackrock Inc. | 0.24% | 29,075 | 41.29K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 2.41% | 291,271 | 413.60K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.60% | 193,423 | 274.66K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.39% | 46,893 | 66.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 43,510 | 61.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 10,327 | 14.66K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 10,005 | 14.21K | Oct 30, 2024 |